Marengo.
Therapeutics

01Who they are, right now

In a lab off Memorial Drive in Cambridge, a drug with a hard-to-pronounce name is doing something checkpoint inhibitors were never built to do: shrinking tumors that stopped responding to the last generation of immunotherapy. The drug is invikafusp alfa. The company is Marengo Therapeutics, and in 2026 it sits in an unusual spot - small enough to fit in a single building, but holding clinical data that keeps landing it on the late-breaking stage at the field's biggest cancer meetings.

Marengo is a clinical-stage biotech with roughly 39 people, one lead drug in human trials, a deep bench of follow-on programs, and two pharma partners - Gilead and Ipsen - who have already written checks. It is not a household name. It is the kind of company oncologists are starting to watch.

Fig 1. The orange T cell, photographed against nothing. Marengo's logo is also its argument: it is all about the cell, not the tumor.

02The problem they saw

Most cancers never feel the immune system at all.

The last decade of oncology belonged to checkpoint inhibitors - drugs like Keytruda and Opdivo that take the brakes off T cells so they can attack tumors. They were a genuine breakthrough. They were also, for most patients, not enough. The brakes only matter if there is a foot on the accelerator. In "cold" tumors, and in patients whose cancer has grown resistant to PD-1 therapy, the cancer-fighting T cells were never switched on in the first place.

That is the gap Marengo built itself around. Releasing a brake does nothing for a car that was never started. The question they asked was deceptively simple: instead of removing an obstacle, could you reach in and turn the right T cells on - selectively, without lighting the whole immune system on fire?

Fig 2. Translation: everyone else was studying the lock. Marengo went looking for a different key.

03The founders' bet

In November 2021, the venture firm Apple Tree Partners - led by founder Seth Harrison - took science it had incubated in its own R&D labs between 2017 and 2021 and spun it out as Marengo Therapeutics, with $80 million to start. To run it, they recruited Zhen Su, a physician-scientist who had led global oncology at Merck KGaA. It was an unusual founding story: the science came first, and the company was built around it on purpose.

The bet was on a part of immune biology most drug developers had walked straight past - the variable (Vβ) region of the T cell receptor. Conventional wisdom said the TCR was too messy, too diverse, too patient-specific to drug. Marengo's wager was the opposite: that hidden in that diversity was a shared switch, one you could press to activate a whole cancer-relevant subset of T cells at once.

Fig 3. A company assembled in the order science fiction promised but biotech rarely delivers: discovery, then money, then a CEO.

04The product

One molecule. Two signals. A whole T cell subset, switched on.

Marengo's engine is the STAR platform - Selective T Cell Activation Repertoire. It builds antibody-fusion molecules that carry two messages in a single shot: the T cell receptor activation signal and the co-stimulation signal a T cell needs to fully commit. Deliver both at once, aimed at the right Vβ subset, and you get what a textbook calls a proper immune response - immediate attack plus long-term memory - without dumping a flood of inflammatory cytokines into the bloodstream.

The lead drug, invikafusp alfa (STAR0602), is the first dual T cell agonist to come off that platform. But Marengo did not stop at one molecule. The platform comes in three volumes:

Fig 4. A platform with three settings - on, engage, off. Marengo built a thermostat for the immune system and is selling it three different ways.

05From spin-out to the late-breaking stage

Fig 5. Five years, five oral presentations, one drug. Biotech timelines are usually measured in disappointments - this one isn't.

06The proof

A clever mechanism is worth nothing until a tumor shrinks. Marengo's case rests on a set of early Phase 2 numbers, presented as monotherapy in TMB-high tumors across seven major solid-tumor types - colorectal, lung, breast, gastric and more - in patients whose cancer had already stopped responding to PD-1 therapy.

Fig 6. The number to sit with is 80% disease control - in patients the previous generation of immunotherapy had already given up on.

Then there is the validation that comes from other people's wallets. Ipsen paid roughly $45M upfront for preclinical STAR activators. Gilead agreed to test invikafusp alfa alongside its own Trodelvy in breast cancer. And the science itself has cleared peer review in Science Translational Medicine and Science Advances.

• Gilead SciencesSTART-002 trial: invikafusp alfa + Trodelvy in metastatic TNBC and HR+/HER2- breast cancers.
• Ipsen~$45M upfront to license and advance partnered STAR and TriSTAR programs.
• University of PennsylvaniaMulti-year precision T cell immunology collaboration across oncology and autoimmune disease.
• King's College LondonCo-authored Science Advances paper describing a new approach to T cell activation.
• NIH / NCI & Mass General (Harvard)Lead clinical trial sites enrolling START-001 patients.

Fig 7. The shortest review of any biotech: who else is willing to pay for the idea. Marengo's list is getting longer.

07The mission

Marengo's stated tagline is not "cure cancer." It is something stranger and more specific: envision lifelong protection from disease. The word that matters there is lifelong. A drug that shrinks a tumor for a few months is a treatment. A drug that teaches the immune system to remember the tumor is closer to protection.

That is why the memory half of the STAR mechanism matters as much as the attack half. By activating natural T cell subsets through the TCR - rather than engineering cells outside the body, the way CAR-T does - Marengo is betting on durability built in, not bolted on. If that holds up in larger trials, the company's own framing is that invikafusp alfa becomes a new immuno-oncology backbone: the thing you start with, not the thing you reach for after everything else fails.

Fig 8. A small team, a big dial. The interesting biotechs are rarely the biggest ones.

08Why it matters tomorrow

Back to that lab off Memorial Drive, and the patient whose cancer had stopped listening to PD-1 therapy. For most of the last decade, that patient was nearly out of options - the brakes were already off, and nothing happened. Marengo's whole reason to exist is that those patients should not be the end of the story.

The data is still early. Phase 2 is not approval, 20% is not a cure, and biotech is a graveyard of elegant mechanisms that never reached a pharmacy. Marengo has earned attention, not a victory lap. But the shape of the bet is clear, and increasingly other people are making it too: that the immune system already knows how to beat cancer, and the job of a drug is not to fight on its behalf - just to wake it up, point it in the right direction, and trust it to remember.

The orange T cell on the white field, in other words, was never decoration. It was the plan.